323 related articles for article (PubMed ID: 22921697)
21. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
[TBL] [Abstract][Full Text] [Related]
22. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
23. Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy.
Kim TH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Scand J Urol; 2017 Feb; 51(1):27-32. PubMed ID: 28168924
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
25. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
26. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Allan RW; Sanderson H; Epstein JI
J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
[TBL] [Abstract][Full Text] [Related]
27. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
[TBL] [Abstract][Full Text] [Related]
28. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.
Dolejsova O; Kucera R; Fuchsova R; Topolcan O; Svobodova H; Hes O; Eret V; Pecen L; Hora M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818787377. PubMed ID: 30021484
[TBL] [Abstract][Full Text] [Related]
29. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
Ahdoot M; Wilbur AR; Reese SE; Lebastchi AH; Mehralivand S; Gomella PT; Bloom J; Gurram S; Siddiqui M; Pinsky P; Parnes H; Linehan WM; Merino M; Choyke PL; Shih JH; Turkbey B; Wood BJ; Pinto PA
N Engl J Med; 2020 Mar; 382(10):917-928. PubMed ID: 32130814
[TBL] [Abstract][Full Text] [Related]
30. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
31. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).
Lellig E; Gratzke C; Kretschmer A; Stief C
World J Urol; 2015 Jul; 33(7):917-22. PubMed ID: 26047652
[TBL] [Abstract][Full Text] [Related]
32. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
[TBL] [Abstract][Full Text] [Related]
33. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
34. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
[TBL] [Abstract][Full Text] [Related]
35. The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.
Villa L; Capitanio U; Briganti A; Abdollah F; Suardi N; Salonia A; Gallina A; Freschi M; Russo A; Castiglione F; Bianchi M; Rigatti P; Montorsi F; Scattoni V
J Urol; 2013 Mar; 189(3):854-9. PubMed ID: 23022004
[TBL] [Abstract][Full Text] [Related]
36. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
37. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
38. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
Loeb S; Roehl KA; Thaxton CS; Catalona WJ
Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
[TBL] [Abstract][Full Text] [Related]
39. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
40. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]